Afif Nakhleh

Dr. Afif Nakhleh

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in World Journal of Diabetes
Verified
Journal Article
Open access
ANAfif Nakhleh
Afif Nakhleh
NSNaim Shehadeh
Naim Shehadeh
Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention

31 July 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
ANAfif Nakhleh
Afif Nakhleh
SSSivan Spitzer
Sivan Spitzer
NSNaim Shehadeh
Naim Shehadeh
The diabetes epidemic which impacts many people globally necessitates patient education to enhance self-management. Artificial intelligence (AI) chatbots hold promise in automizing patient education and lessening healthcare providers’ burden. This study assesses the utility of ChatGPT, an AI chatbot created by OpenAI, in responding to the diabetes knowledge questionnaire (24-DKQ). The 24-DKQ, consisting of 24 items, is specifically designed to evaluate patients’ diabetes knowledge. We found that ChatGPT accurately answered all 24 questions of the 24-DKQ, and was also able to expand and provide decent explanations. AI technology can serve as an opportunity to create personalized and automated diabetes patient education materials. However, despite AI technology’s great potential, its effectiveness remains unclear. It is crucial for researchers, developers, and healthcare professionals to collaborate in order to create AI programs that are validated, reliable, and accurately tailored to the individual needs of people living with diabetes.

1 July 2016 in Hormones
Verified
Journal Article
Closed access
ANAfif Nakhleh
Afif Nakhleh
LSLeonard Saiegh
Leonard Saiegh
MRMaria Reut
Maria Reut
MAMohammad Sheikh Ahmad
Mohammad Sheikh Ahmad
IPIrit Wirsansky Pearl
Irit Wirsansky Pearl
CSCarmela Shechner
Carmela Shechner
Cushing's disease during pregnancy is associated with an increased risk for maternal and fetal complications. In recurrent Cushing`s disease following transsphenoidal surgery, and when re-operation is not feasible, medical treatment is usually considered. Cabergoline was found to be effective in reducing hypercortisolism in Cushing's disease. Evolving data concerning the safety of cabergoline use during pregnancy show no significant increase in the rate of complications during pregnancy or the postnatal period. We report a 29-year-old woman, gravida 0, para 0, with recurrent Cushing`s disease, three years after transsphenoidal resection of pituitary ACTH-secreting macroadenoma. Repeated MRI revealed an empty sella with a small gadolinium-enhancing lesion, suspected to be an adenoma remnant on the medial wall of the right cavernous sinus. As the patient was not willing to undergo repeat surgical intervention, treatment with cabergoline was initiated, with a gradual dose titration up to 3.5 mg/week. Clinical improvement ensued, and 4 months later, she conceived spontaneously. After discussing treatment options with the patient, cabergoline treatment at a dose of 2 mg/week was continued throughout pregnancy. The patient showed complete clinical remission during pregnancy. Consecutive tests of 24-h urinary free cortisol concentration were not found to be elevated. Pregnancy and delivery were uneventful except for mild hypothyroidism observed during the second trimester. At full term the patient delivered a healthy female infant, by an elective cesarean section. This case report demonstrates that cabergoline may be an effective and safe therapeutic option for the treatment of Cushing's disease during pregnancy.

13 April 2018 in Pituitary
Verified
Journal Article
Closed access
PDF file
ANAfif Nakhleh
Afif Nakhleh
NSNaim Shehadeh
Naim Shehadeh
IHIrit Hochberg
Irit Hochberg
MZMoshe Zloczower
Moshe Zloczower
SZSagit Zolotov
Sagit Zolotov
DNDeeb Daoud Naccache
Deeb Daoud Naccache

15 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZVZahava Vadasz
Zahava Vadasz
TRTova Rainis
Tova Rainis
ANAfif Nakhleh
Afif Nakhleh
THTharwat Haj
Tharwat Haj
JBJacob Bejar
Jacob Bejar
ETElias Toubi
Elias Toubi
Immune semaphorins are a large family of proteins involved in the pathogenesis of inflammatory diseases through the regulation of immune homeostasis and tissue inflammation. We aim to assess the possible involvement of semaphorin3A (sema3A) and 4A (sema4A) in peripheral immune responses and bowel tissue inflammation of patients suffering from Crohn’s disease (CD) and ulcerative colitis (UC). Twenty-seven CD patients and 10 UC patients were studied and compared to 10 patients followed for acute diverticulitis (disease control) and 12 healthy individuals. All were evaluated for sema3A expression on T regulatory cells (Tregs), serum levels of sema3A and sema4A, and tissue expression of sema3A and sema4A in bowel biopsies. The percentage (%) of T regulatory cells (Tregs) expressing sema3A in patients with active CD (64.5% ±14.49%) and active UC (49.8% ±16.45%) was significantly lower when compared to that of healthy controls (88.7% ±3.6%, p< 0.001 and p< 0.0001, respectively). This expression was seen to be in negative correlation with CD activity. Serum levels of Sema4A were significantly lower in patients with CD and UC when compared to that of controls (5.69±1.48ng\ml for CD, 5.26±1.23 ng/ml for UC patients vs 9.74±2.73ng/ml for normal controls, P<0.001). Sema4A was highly expressed in lymphocytes of the lamina propria of CD and UC patients but absent in patients with diverticulitis or in normal individuals. Altered % of Tregs expressing sema3A in patients with inflammatory bowel diseases (IBD) is partially responsible for their failure in preventing CD4+ effector T cell induced inflammation in IBD in peripheral blood. The increased expression of sema4A in bowel biopsies from CD and UC patients is suggestive of its central role in regulating local tissue inflammation in the bowel.

19 January 2021 in Pituitary
Verified
Journal Article
Closed access
PDF file
ANAfif Nakhleh
Afif Nakhleh
MNMai Assaliya Naffa
Mai Assaliya Naffa
GSGill Sviri
Gill Sviri
NSNaim Shehadeh
Naim Shehadeh
IHIrit Hochberg
Irit Hochberg